New PET scan imaging test for solid tumors
Part of Cancer clinical trials.
This trial tests a new type of PET scan (a special imaging test) called 89Zr-s-C1 to help detect and monitor solid tumors like melanoma, gastric cancer, or colorectal cancer. The scan may help doctors see tumors more clearly and track whether treatment is working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Pathologically confirmed (biopsy-proven) solid tumor that is newly diagnosed, recently recurred, or suspected to have recurred
- Blood counts and liver/kidney function tests within acceptable ranges
- Expected to live at least 12 weeks
- At least one measurable tumor visible on imaging (RECIST criteria)
- Able to lie flat for 30 minutes without moving
- Willing and able to follow study instructions and sign consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new imaging agent that targets TF-antigen, a molecule found on many solid tumors. The goal is to see if a PET scan can better detect and monitor cancers like lung, breast, or colon cancer.
This trial is testing a new imaging agent called RT01-89Zr to see if it can help detect solid tumors during PET/CT scans. It involves an injection of the agent followed by imaging, and may offer a more targeted way to visualize tumors.
This trial tests a new type of imaging scan that uses a special tracer to help doctors see solid tumors more clearly. The scan may help improve how tumors are detected and monitored during treatment.
This trial uses a special PET scan to take pictures of certain solid tumors. The scan uses a new dye that may help doctors see the tumors more clearly. You may be eligible if you have one of the listed cancers and are between 18 and 75 years old with good daily function.
This trial uses a new kind of PET/CT scan to take detailed pictures of solid tumors such as melanoma, liver, lung, breast, pancreatic, or ovarian cancer. The scan might help doctors find cancer more clearly.
This trial tests a special imaging agent (a nanobody probe) that targets a protein called CD147 on tumor cells. If you have a solid tumor like melanoma, liver, colorectal, pancreatic, breast, stomach, or lung cancer, the PET scan may help doctors see your cancer more clearly.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.